Zhejiang Wenda Pharmaceutical Technology Co., Ltd.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data…